Efficacy of influenza vaccination of elderly rhesus macaques is dramatically improved by addition of a cationic lipid/dna adjuvant

Timothy D. Carroll, Shannon R. Matzinger, Peter A Barry, Michael B. McChesney, Jeffery Fairman, Chris J Miller

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background. The decreased immune response among elderly individuals results in reduced influenza vaccine efficacy. Strategies to improve vaccine efficacy in elderly individuals are needed. The goal of this study was to determine whether a cationic lipid/DNA complex (CLDC) can improve the efficacy of the trivalent inactivated influenza vaccine Fluzone in elderly nonhuman primates.Methods. Elderly (age, >18 years) rhesus macaques were vaccinated with Fluzone, with or without CLDC, and challenged with a human seasonal influenza virus isolate, A/Memphis/7/2001(H1N1).Results. We found that elderly macaques have significantly lower levels of circulating naive CD4+ T cells, naive CD8+ T cells, and B cells as compared to juvenile monkeys. Furthermore, on the day of challenge, recipients of Fluzone/CLDC had significantly higher plasma anti-influenza virus immunoglobulin G (P <. 001) and immunoglobulin A (P <. 001) titers than recipients of Fluzone alone. After virus challenge, only the Fluzone/CLDC-vaccinated animals had a significantly lower level of virus replication (P <. 01) relative to the unvaccinated control animals.Conclusions. These results demonstrate that CLDC can enhance the immunogenicity and efficacy of a licensed TIV in immunosenescent elderly monkeys.

Original languageEnglish (US)
Pages (from-to)24-33
Number of pages10
JournalJournal of Infectious Diseases
Volume209
Issue number1
DOIs
StatePublished - Jan 1 2014

Fingerprint

Macaca mulatta
Human Influenza
Vaccination
Lipids
DNA
Influenza Vaccines
Orthomyxoviridae
Haplorhini
T-Lymphocytes
Inactivated Vaccines
Macaca
Virus Replication
Immunoglobulin A
Primates
B-Lymphocytes
Vaccines
Immunoglobulin G
Viruses

Keywords

  • antibody titers
  • CD8+ T cells
  • elderly
  • immunosenescence
  • inactivated vaccine
  • macaques
  • mucosal

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy

Cite this

Efficacy of influenza vaccination of elderly rhesus macaques is dramatically improved by addition of a cationic lipid/dna adjuvant. / Carroll, Timothy D.; Matzinger, Shannon R.; Barry, Peter A; McChesney, Michael B.; Fairman, Jeffery; Miller, Chris J.

In: Journal of Infectious Diseases, Vol. 209, No. 1, 01.01.2014, p. 24-33.

Research output: Contribution to journalArticle

Carroll, Timothy D. ; Matzinger, Shannon R. ; Barry, Peter A ; McChesney, Michael B. ; Fairman, Jeffery ; Miller, Chris J. / Efficacy of influenza vaccination of elderly rhesus macaques is dramatically improved by addition of a cationic lipid/dna adjuvant. In: Journal of Infectious Diseases. 2014 ; Vol. 209, No. 1. pp. 24-33.
@article{035e8e48300d456790c880cbd360e6a6,
title = "Efficacy of influenza vaccination of elderly rhesus macaques is dramatically improved by addition of a cationic lipid/dna adjuvant",
abstract = "Background. The decreased immune response among elderly individuals results in reduced influenza vaccine efficacy. Strategies to improve vaccine efficacy in elderly individuals are needed. The goal of this study was to determine whether a cationic lipid/DNA complex (CLDC) can improve the efficacy of the trivalent inactivated influenza vaccine Fluzone in elderly nonhuman primates.Methods. Elderly (age, >18 years) rhesus macaques were vaccinated with Fluzone, with or without CLDC, and challenged with a human seasonal influenza virus isolate, A/Memphis/7/2001(H1N1).Results. We found that elderly macaques have significantly lower levels of circulating naive CD4+ T cells, naive CD8+ T cells, and B cells as compared to juvenile monkeys. Furthermore, on the day of challenge, recipients of Fluzone/CLDC had significantly higher plasma anti-influenza virus immunoglobulin G (P <. 001) and immunoglobulin A (P <. 001) titers than recipients of Fluzone alone. After virus challenge, only the Fluzone/CLDC-vaccinated animals had a significantly lower level of virus replication (P <. 01) relative to the unvaccinated control animals.Conclusions. These results demonstrate that CLDC can enhance the immunogenicity and efficacy of a licensed TIV in immunosenescent elderly monkeys.",
keywords = "antibody titers, CD8+ T cells, elderly, immunosenescence, inactivated vaccine, macaques, mucosal",
author = "Carroll, {Timothy D.} and Matzinger, {Shannon R.} and Barry, {Peter A} and McChesney, {Michael B.} and Jeffery Fairman and Miller, {Chris J}",
year = "2014",
month = "1",
day = "1",
doi = "10.1093/infdis/jit540",
language = "English (US)",
volume = "209",
pages = "24--33",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Efficacy of influenza vaccination of elderly rhesus macaques is dramatically improved by addition of a cationic lipid/dna adjuvant

AU - Carroll, Timothy D.

AU - Matzinger, Shannon R.

AU - Barry, Peter A

AU - McChesney, Michael B.

AU - Fairman, Jeffery

AU - Miller, Chris J

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background. The decreased immune response among elderly individuals results in reduced influenza vaccine efficacy. Strategies to improve vaccine efficacy in elderly individuals are needed. The goal of this study was to determine whether a cationic lipid/DNA complex (CLDC) can improve the efficacy of the trivalent inactivated influenza vaccine Fluzone in elderly nonhuman primates.Methods. Elderly (age, >18 years) rhesus macaques were vaccinated with Fluzone, with or without CLDC, and challenged with a human seasonal influenza virus isolate, A/Memphis/7/2001(H1N1).Results. We found that elderly macaques have significantly lower levels of circulating naive CD4+ T cells, naive CD8+ T cells, and B cells as compared to juvenile monkeys. Furthermore, on the day of challenge, recipients of Fluzone/CLDC had significantly higher plasma anti-influenza virus immunoglobulin G (P <. 001) and immunoglobulin A (P <. 001) titers than recipients of Fluzone alone. After virus challenge, only the Fluzone/CLDC-vaccinated animals had a significantly lower level of virus replication (P <. 01) relative to the unvaccinated control animals.Conclusions. These results demonstrate that CLDC can enhance the immunogenicity and efficacy of a licensed TIV in immunosenescent elderly monkeys.

AB - Background. The decreased immune response among elderly individuals results in reduced influenza vaccine efficacy. Strategies to improve vaccine efficacy in elderly individuals are needed. The goal of this study was to determine whether a cationic lipid/DNA complex (CLDC) can improve the efficacy of the trivalent inactivated influenza vaccine Fluzone in elderly nonhuman primates.Methods. Elderly (age, >18 years) rhesus macaques were vaccinated with Fluzone, with or without CLDC, and challenged with a human seasonal influenza virus isolate, A/Memphis/7/2001(H1N1).Results. We found that elderly macaques have significantly lower levels of circulating naive CD4+ T cells, naive CD8+ T cells, and B cells as compared to juvenile monkeys. Furthermore, on the day of challenge, recipients of Fluzone/CLDC had significantly higher plasma anti-influenza virus immunoglobulin G (P <. 001) and immunoglobulin A (P <. 001) titers than recipients of Fluzone alone. After virus challenge, only the Fluzone/CLDC-vaccinated animals had a significantly lower level of virus replication (P <. 01) relative to the unvaccinated control animals.Conclusions. These results demonstrate that CLDC can enhance the immunogenicity and efficacy of a licensed TIV in immunosenescent elderly monkeys.

KW - antibody titers

KW - CD8+ T cells

KW - elderly

KW - immunosenescence

KW - inactivated vaccine

KW - macaques

KW - mucosal

UR - http://www.scopus.com/inward/record.url?scp=84891368229&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891368229&partnerID=8YFLogxK

U2 - 10.1093/infdis/jit540

DO - 10.1093/infdis/jit540

M3 - Article

C2 - 24141979

AN - SCOPUS:84891368229

VL - 209

SP - 24

EP - 33

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 1

ER -